IP Library › Granted Patent US 10,905,775
Granted Patent B2
US 10,905,775 · App. 13/905,015 · Granted Feb 2, 2021

Particulate constructs for release of active agents

Inventors: Lawrence D. Mayer (North Vancouver, CA); Robert K. Prud'homme (Lawrenceville, NJ); Christine J. Allen (Toronto, CA); Walid S. Saad (Princeton, NJ)
Assignees: Celator Pharmaceuticals, Inc.; The Trustees of Princeton University
A61K47/6931A61K8/85A61K9/5153A61K45/06A61K47/22A61K47/54A61K47/543A61K47/545A61K47/55A61K47/551A61K47/552A61K47/58A61K47/59A61K47/593A61K47/60A61K47/6935A61Q17/04B82Y5/00A61K2800/57
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,905,775
App. No.
13/905,015
Granted
Feb 2, 2021
Kind
B2
Abstract

Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments.

Claims (22)

1. A composition comprising particles obtained from fast mixing according to the Nano Precipitation process

a) an amphiphilic stabilizer,

b) a conjugate of the formula

(active−linker) n −hydrophobic moiety  (1)

wherein n is an integer of 1-100;

“active” refers to a first therapeutic agent;

“linker” is a divalent residue of an organic molecule which comprises a bond that is selectively cleavable by reduction or hydrolysis to control the rate of release of said active from the particles free of said hydrophobic moiety or portion thereof; and

“hydrophobic moiety” refers to the residue of an organic molecule that is insoluble in aqueous solution; and

c) a second therapeutic agent different from the first therapeutic agent to obtain said particles,

and wherein the hydrophobic moiety is a polymer having a molecular weight between 800 and 200,000 g/mole or is a natural product, and the amphiphilic stabilizer is a copolymer having a hydrophilic region and a hydrophobic region wherein said copolymer is a graft, block or random amphiphilic copolymer and has a molecular weight between 1,000 g/mole and 50,000 g/mole.

2. The composition of claim 1 wherein the hydrophobic moiety is a polymer of methyl acrylate, ethyl acrylate, propyl acrylate, n-butyl acrylate (BA), isobutyl acrylate, 2-ethyl acrylate, t-butyl acrylate, ethyl methacrylate, n-butyl methacrylate, isobutyl methacrylate, an acrylonitrile, a methacrylonitrile, vinyl acetate, vinylversatate, vinylpropionate, vinylformamide, vinylacetamide, vinylpyridine, vinylimidazole; an aminoalkylacrylate, an aminoalkylmethacrylate, an aminoalkyl(meth)acrylamide, a styrene, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropylmethylcellulose phthalate, or

is poly(D,L lactide), poly(D,L-lactide-co-glycolide), poly(glycolide), poly(hydroxybutyrate), poly(alkylcarbonate), a poly(orthoester), a polyester, poly(hydroxyvaleric acid), polydioxanone, poly(ethylene terephthalate), poly(malic acid), poly(tartronic acid), a polyanhydride, a polyphosphazene, a poly(amino acid) and copolymers, a poly(ethylene-vinyl acetate) (“EVA”) copolymer, silicone rubber, polyethylene, polypropylene, a polydiene, a maleic anhydride copolymer of vinyl-methylether and other vinyl ethers, a polyamide (nylon 6,6), a polyurethane, a poly(ester urethane), a poly(ether urethane), a poly(ester-urea), poly(valerolactone), a polyanhydride, a copolymer of poly(caprolactone) and poly(lactic acid), or

is a natural product which is vitamin E, vitamin K, vitamin A, beta carotene, astaxanthin, trans and cis retinal, retinoic acid, folic acid, dihydrofolate, retinyl acetate, retinyl palmitate), cholecalciferol, calcitriol, hydroxycholecalciferol, ergocalciferol, a-tocopherol, a-tocopherol acetate, a-tocopherol nicotinate, or estradiol.

3. The composition of claim 1 wherein the amphiphilic stabilizer is a copolymer of a hydrophilic block coupled with a hydrophobic block,

wherein the hydrophobic block is methyl acrylate, ethyl acrylate, propyl acrylate, n-butyl acrylate (BA), isobutyl acrylate, 2-ethyl acrylate, t-butyl acrylate, ethyl methacrylate, n-butyl methacrylate, isobutyl methacrylate, an acrylonitrile; methacrylonitrile, vinyl acetate, vinylversatate, vinylpropionate, vinylformamide, vinylacetamide, vinylpyridine, vinylimidazole, an aminoalkylmethacrylate, an aminoalkyl(meth)acrylamide, styrene, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropylmethylcellulose phthalate, poly(D,L lactide), poly (D,L-lactide-co-glycolide), poly(glycolide), poly(hydroxybutyrate), poly(alkylcarbonate), a poly(orthoester), a polyester, poly(hydroxyvaleric acid), polydioxanone, poly(ethylene terephthalate), poly(malic acid), poly(tartronic acid), a polyanhydride, a polyphosphazene, a poly(amino acid), a poly(ethylene-vinyl acetate) (“EVA”) copolymer, silicone rubber, polyethylene, polypropylene, a polydiene, a hydrogenated form of polydiene), maleic anhydride copolymers of vinyl methylether and other vinyl ethers, polyamides (nylon 6,6), polyurethane, poly(ester urethanes), poly(ether urethanes), poly(ester-urea), poly(ethylenevinyl acetate), poly(D,L-lactic acid), poly(L-lactic acid), poly(glycolic acid), a copolymer of lactic acid and glycolic acid, poly(caprolactone), poly(valerolactone), a polyanhydride, a copolymer of poly(caprolactone) and poly(lactic acid); and

the hydrophilic block is a carboxylic acid, a polyoxyethylene, a polyacrylamide, a copolymer of acrylamide with dimethylaminoethylmethacrylate, diallyldimethylammonium chloride, vinylbenzylthrimethylammonium chloride, acrylic acid, methacrylic acid, 2-acrylamido-2-methylpropane sulfonic acid, styrene sulfonate, polyvinyl pyrrolidone, starch, a starch derivative, dextran, a dextran derivative, a polypeptide, poly hyaluronic acid, an alginic acid, a polylactide, a polyethyleneimine, a polyionene, a polyacrylic acid, a polyiminocarboxylate, gelatin, or an unsaturated ethylenic mono or dicarboxylic acid.

4. The composition of claim 1 , wherein the hydrophobic moiety is vitamin E, vitamin A or vitamin K, or a retinol; or

wherein the hydrophobic moiety is polycaprolactone, polylactic acid, polystyrene, polybutadiene, polycaproic acid, polymethylbenzylate, poly(D,L-lactide), poly(D,L-lactide-co-glycolide), poly(glycolide), poly(hydroxybutyrate), poly(alkylcarbonate) poly(orthoesters), polyesters, poly(hydroxyvaleric acid), or copolymers thereof.

5. The composition of claim 1 , wherein the amphiphilic stabilizer is methoxypolyethylene glycol (mPEG)-polycaprolactone (PCL), mPEG-polystyrene, mPEG-polybutadiene, mPEG-polylactate, block copolymers of polyethylene oxide, and polypropylene oxide, or block copolymers of polyethylene oxide and polybutylene oxide.

6. The composition of claim 1 , wherein the particulate constructs comprise 10 3 -10 7 conjugates of formula (1).

7. The composition of claim 1 , wherein the particulate constructs have an average diameter less than 5 μ.

8. The composition of claim 1 wherein said first therapeutic agent is present in the form of formula (1) and the second therapeutic agent is in unbound form.

Assignments (8)
CORRECTIVE ASSIGNMENT TO CORRECT THE REMOVE 2 APPLICATION NUMBERS PREVIOUSLY RECORDED AT REEL: 07234 FRAME: 0137. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Oct 9, 2025
From: CELATOR PHARMACEUTICALS, INC.
To: JAZZ PHARMACEUTICALS THERAPEUTICS, INC.
Reel/Frame 073133/0142 →
CORRECTIVE ASSIGNMENT TO CORRECT THE REMOVAL OF 8 PROPERTY NUMBERS PREVIOUSLY RECORDED AT REEL: 072341 FRAME: 0137. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Oct 8, 2025
From: CELATOR PHARMACEUTICALS, INC.
To: JAZZ PHARMACEUTICALS THERAPEUTICS, INC.
Reel/Frame 073058/0985 →
CHANGE OF NAME Recorded Aug 7, 2025
From: CELATOR PHARMACEUTICALS, INC.
To: JAZZ PHARMACEUTICALS THERAPEUTICS, INC.
Reel/Frame 072341/0137 →
SECURITY AGREEMENT Recorded May 5, 2021
From: CAVION, INC.; CELATOR PHARMACEUTICALS, INC.; JAZZ PHARMACEUTICALS IRELAND LIMITED; JAZZ PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056151/0010 →
RELEASE OF SECURITY INTEREST Recorded May 5, 2021
From: BANK OF AMERICA, N.A.
To: JAZZ PHARMACEUTICALS, INC.; JAZZ PHARMACEUTICALS IRELAND LIMITED; JAZZ PHARMACEUTICALS INTERNATIONAL LIMITED; JAZZ PHARMACEUTICALS INTERNATIONAL III LIMITED; CELATOR PHARMACEUTICALS, INC.; CAVION, INC.
Reel/Frame 056150/0708 →
SECURITY AGREEMENT Recorded Jul 12, 2016
From: CELATOR PHARMACEUTICALS, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 039312/0397 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2013
From: MAYER, LAWRENCE D.; ALLEN, CHRISTINE J.
To: CELATOR PHARMACEUTICALS, INC.
Reel/Frame 030858/0007 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2013
From: PRUD'HOMME, ROBERT K.; SAAD, WALID S.
To: THE TRUSTEES OF PRINCETON UNIVERSITY
Reel/Frame 030858/0115 →
Continuity (3)
Continuation 11632884
Provisional Application 60589164 · Jul 19, 2004
Related Publication 20130336915A1 · Dec 19, 2013
Cited By (15)
US 12,186,296 US 12,186,298 US 12,226,377 US 12,226,388 US 12,226,389 US 12,239,625 US 12,257,223 US 12,263,150 US 12,263,151 US 12,295,926 US 12,303,478 US 12,478,604 US 12,551,457 US 12,642,811 US 12,728,110